Quarterly ResultMay 7, 2026, 04:34 PM
Lexicon Q1 Net Loss $(1.04)M; Revenues $21.1M; Raises $96.2M Equity
AI Summary
Lexicon Pharmaceuticals reported a significantly improved Q1 2026 with a net loss of $(1.04) million, a substantial reduction from $(25.3) million in Q1 2025. Total revenues surged to $21.1 million, primarily driven by $20 million in licensing and milestone revenue. The company strengthened its financial position by raising approximately $96.2 million through common and preferred stock issuances and secured a new $100 million Hercules Term Loan facility, using the initial $55 million tranche to repay its Oxford Term Loans. Lexicon continues to advance its pipeline, including INPEFA commercialization and clinical trials for sotagliflozin and pilavapadin.
Key Highlights
- Q1 2026 net loss significantly improved to $(1.04) million from $(25.3) million in Q1 2025.
- Total revenues for Q1 2026 increased to $21.1 million from $1.3 million in Q1 2025.
- Licensing and milestone revenue contributed $20.0 million in Q1 2026.
- Raised $40.6 million net from common stock public offering in February 2026.
- Raised $55.6 million gross from private placement of common and preferred stock in February 2026.
- Secured new $100 million Hercules Term Loans, with $55 million funded on May 4, 2026.
- Repaid Oxford Term Loans, which had a $49.7 million carrying value.
- Cash and cash equivalents increased to $38.1 million at March 31, 2026.